ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,779Medicare Part D Prescriptions Filled, Including Refills

Rank: 7 out of 25

$428K Total Retail Price of All Prescriptions

Rank: 7 out of 25

358 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
69% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 358 patients filled at least one prescription for a schedule two drug, compared to an average of 16%.

Schedule Three
Controlled Substances

18% of this provider’s 358 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

0% of this provider’s 7,367 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $48 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LEVOTHYROXINE SODIUM 514 464 1 2
FUROSEMIDE 363 300 2 5
SIMVASTATIN 349 301 3 4
HYDROCODONE-ACETAMINOPHEN 343 309 S3 4 7
WARFARIN SODIUM 295 225 5 8
LISINOPRIL 251 233 6 3
AMLODIPINE BESYLATE 232 221 7 6
DONEPEZIL HCL 206 199 8 19
NAMENDA 196 189 9 21
METOPROLOL TARTRATE 189 174 10 9
OMEPRAZOLE 174 156 11 1
CITALOPRAM HBR 148 130 12 10
TRAZODONE HCL 131 120 13 18
METFORMIN HCL 129 111 14 13
ATENOLOL 121 104 15 11
OXYCODONE HCL 115 84 S2 16 23
DIVALPROEX SODIUM 112 71 17 46
POLYETHYLENE GLYCOL 3350 110 86 18 27
GABAPENTIN 100 50 19 17
ATORVASTATIN CALCIUM 98 80 20 22
OXYCODONE-ACETAMINOPHEN 98 43 S2 20 47
HYDROCHLOROTHIAZIDE 95 90 22 14
CYMBALTA 94 46 23 41
SERTRALINE HCL 89 78 24 24
ALENDRONATE SODIUM 87 85 25 20
TRAMADOL HCL 82 70 26 39
FENTANYL 81 75 S2 27 53
LOSARTAN POTASSIUM 80 77 28 15
KLOR-CON M20 78 53 29 65
TAMSULOSIN HCL 77 74 30 28
GLIPIZIDE 75 73 31 35
POTASSIUM CHLORIDE 70 62 32 12
ZOLPIDEM TARTRATE 67 52 33 38
RISPERIDONE 66 37 34 69
CIPROFLOXACIN HCL 63 63 35 66
ESCITALOPRAM OXALATE 59 47 36 32
PREDNISONE 57 50 37 40
LOVASTATIN 56 51 38 25
IPRATROPIUM-ALBUTEROL 53 45 39 101
DIGOXIN 53 53 39 33
CARVEDILOL 52 51 41 30
ABILIFY 52 35 41 150
OLANZAPINE 51 51 43 73
DILTIAZEM HCL 51 51 43 154
TRIAMCINOLONE ACETONIDE 50 34 45 59
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 30, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.